Review of vaccine price data

Review of vine prie dt Sumitted y WHO Europen Region Memer Sttes through the WHO/UNICEF Joint Reporting Form for 2013

Review of vine prie dt Sumitted y WHO Europen Region Memer Sttes through the WHO/UNICEF Joint Reporting Form for 2013

Astrt This report ims to ssist ntionl immuniztion progrmme mngers, helth udgeting experts nd experts responsile for vine prourement in essing, understnding nd utilizing ville vine mrket informtion in order to improve the effiieny of vine prourement nd ountries ilities to mke finnilly sustinle, informed deisions on vine prourement nd new vine introdution. It onsolidtes dt tht were olleted for the yer 2013 nd provided y 23 Memer Sttes of the WHO Europen Region through the Joint Reporting Form (JRF) of WHO nd the United Ntions Children s Fund (UNICEF). The report provides rief overview of the vilility nd trnspreny of vine priing informtion t the ountry level, the vine prourement mehnisms, the proured vines nd vine prie informtion for eh of the individul vine produts. Individul prourement reords inlude some of the vriles expeted to hve potentil impt on prie, inluding the ountry inome group, volume of prourement, produt formultion nd presenttion, delivery terms nd vine prourement mehnism. World Helth Orgniztion 2015 All rights reserved. The Regionl Offie for Europe of the World Helth Orgniztion welomes requests for permission to reprodue or trnslte its pulitions, in prt or in full. Keywords DATA ANALYSIS PRICING UNICEF VACCINES WORLD HEALTH ORGANIZATION ISBN 978 92 890 5107 1 Address requests out pulitions of the WHO Regionl Offie for Europe to: Pulitions WHO Regionl Offie for Europe UN City, Mrmorvej 51 DK-2100 Copenhgen Ø, Denmrk Alterntively, omplete n online request form for doumenttion, helth informtion, or for permission to quote or trnslte, on the Regionl Offie wesite (http://www.euro.who.int/purequest). The designtions employed nd the presenttion of the mteril in this pulition do not imply the expression of ny opinion whtsoever on the prt of the World Helth Orgniztion onerning the legl sttus of ny ountry, territory, ity or re or of its uthorities, or onerning the delimittion of its frontiers or oundries. Dotted lines on mps represent pproximte order lines for whih there my not yet e full greement. The mention of speifi ompnies or of ertin mnufturers produts does not imply tht they re endorsed or reommended y the World Helth Orgniztion in preferene to others of similr nture tht re not mentioned. Errors nd omissions exepted, the nmes of proprietry produts re distinguished y initil pitl letters. All resonle preutions hve een tken y the World Helth Orgniztion to verify the informtion ontined in this pulition. However, the pulished mteril is eing distriuted without wrrnty of ny kind, either express or implied. The responsiility for the interprettion nd use of the mteril lies with the reder. In no event shll the World Helth Orgniztion e lile for dmges rising from its use. The views expressed y uthors, editors, or expert groups do not neessrily represent the deisions or the stted poliy of the World Helth Orgniztion. Imges M. Bring over WHO pge VI WHO/I. Sergienko pge 6, 19 & 22

III Contents ACKNOWLEDGEMENTS... IV ABBREVIATIONS... V INTRODUCTION... 1 GLOBAL RECOGNITION OF THE NEED FOR VACCINE PRICE TRANSPARENCY... 1 WHO EUROPEAN REGION RESPONSE ON VACCINE PRICE TRANSPARENCY... 2 REPORTING OF VACCINE PRICE DATA... 3 AVAILABILITY AND TRANSPARENCY OF VACCINE PRICING INFORMATION... 4 VACCINE PROCUREMENT MECHANISMS... 5 PROCURED VACCINES... 7 MANUFACTURER BASE OF PROCURED VACCINES... 9 REPORTED VACCINE PRICES... 11 COUNTRY INCOME LEVEL AND VACCINE PRICES PAID... 13 VACCINE PROCUREMENT VOLUMES AND PRICE... 14 VACCINE PRESENTATION AND PRICE... 15 VACCINE FORMULATION AND PRICE... 15 WHO S V3P PLATFORM... 18 REFERENCES... 20 APPENDIX 1. JRF TEMPLATE USED TO COLLECT VACCINE PRICING DATA FOR 2013... 23 APPENDIX 2. MEMBER STATES REPORTING STATUS OF VACCINE PRICING DATA IN THE ANNUAL WHO/UNICEF JRF, 2013... 24 APPENDIX 3. COUNTRY-SPECIFIC VACCINE PRICE DATA BY INDIVIDUAL PRODUCT... 25 APPENDIX 4. NATIONAL CURRENCY EXCHANGE RATES TO US DOLLARS... 41 APPENDIX 5. CLASSIFICATION OF MEMBER STATES BY COUNTRY INCOME GROUP... 43 APPENDIX 6. LIST OF WHO PREQUALIFIED VACCINES AS OF 1 JANUARY 2015... 45 APPENDIX 7. OTHER VACCINE PRICE DATA SOURCES... 51

Aknowledgements This pulition ws developed y the Vine-preventle Diseses nd Immuniztion Progrmme of the WHO Regionl Offie for Europe nd ws oordinted y Oleg Benes, Tehnil Offier t the Regionl Offie, within the frmework of the glol WHO Vine Produt, Prie nd Prourement (V3P) Projet. The following individuls hve ontriuted to the prodution of the pulition nd their inputs re knowledged with sinere grtitude: Shwn S. Gilhrist, independent onsultnt; Srh Shmitt, independent onsultnt, finning, plnning nd prourement; Stephnie Mrit, Vine Produt, Prie nd Prourement (V3P) Projet, WHO hedqurters; Tni Cernushi, Tehnil Offier, Vine Priing, Supply nd Prourement, WHO hedqurters; Mihel Hinsh, independent onsultnt, Vine Produt, Prie nd Prourement (V3P) Projet, WHO hedqurters; Miloud Kddr, Helth Eonomist, WHO hedqurters; Cthrin de Kt-Reynen, Consultnt, Vine-preventle Diseses nd Immuniztion, WHO Regionl Offie for Europe.

V Arevitions P ellulr pertussis BCG ille Clmette Guérin (tuerulosis) vine EVAP Europen Vine Ation Pln 2015 2020 GNI gross ntionl inome FCA free rrier Influenz_dult sesonl influenz vine, dult formultion PCV pneumool onjugte vine PFS pre-filled syringe DT diphtheri nd tetnus toxoids, peditri formultion DTP diphtheri nd tetnus toxoids nd ellulr pertussis vine, peditri formultion DTP-Hi diphtheri nd tetnus toxoids nd ellulr pertussis nd Hemophilus influenze type vine DTP-Hi-HepB-IPV diphtheri nd tetnus toxoids nd ellulr pertussis, Hemophilus influenze type, heptitis B nd intivted poliovirus vine DTP-Hi-IPV diphtheri nd tetnus toxoids nd ellulr pertussis, Hemophilus influenze type nd intivted poliovirus vine DTP-IPV diphtheri nd tetnus toxoids nd ellulr pertussis nd intivted poliovirus vine DT-IPV diphtheri nd tetnus toxoids nd intivted poliovirus vine DTP diphtheri tetnus pertussis vine DTwP diphtheri nd tetnus toxoids nd whole-ell pertussis vine, peditri formultion DTwP-Hi-HepB diphtheri nd tetnus toxoids nd whole-ell pertussis, Hemophilus influenze type nd heptitis B vine GVAP Glol Vine Ation Pln HepA heptitis A vine HepAHepB heptitis A nd heptitis B vine HepB_dult heptitis B vine, dult formultion HepB_peditri heptitis B vine, peditri formultion Hi Hemophilus influenze type HiMenC Hemophilus influenze type nd meningool serogroup C vine HIC high-inome ountry HPV humn ppillomvirus Inoterms Set of rules pulished y the Interntionl Chmer of Commere defining the responsiilities of sellers nd uyers for the delivery of goods under sles ontrts CIF ost insurne nd freight CIP rrige nd insurne pid to DAP delivered t ple DDP delivered duty pid EXW ex works Influenz_peditri sesonl influenz vine, peditri formultion IPV intivted poliovirus vine JE Jpnese enephlitis live ttenuted vine JE_intd Jpnese enephlitis intivted vine JRF WHO/UNICEF Joint Reporting Form LIC low-inome ountry LMIC lower-middle-inome ountry Men AC ivlent meningool A nd C vine Men ACWY qudrivlent meningool A, C, W nd Y vine MenC_onj meningool C onjugte vine MIC middle-inome ounty MMR mesles, mumps nd ruell vine MMRV mesles, mumps, ruell nd vriell vine MR mesles ruell vine OPV orl poliovirus vine Pneumo_ps pneumool polyshride vine TBE tik-orne enephlitis Td tetnus nd diphtheri vine, dult/dolesent formultion TdP tetnus, diphtheri nd ellulr pertussis vine, dult/dolesent formultion Tdp-IPV tetnus, diphtheri, ellulr pertussis nd intivted poliovirus vine, dult/ dolesent formultion TT tetnus toxoid Typhoid-heptitis A typhoid fever nd heptitis A vine UMIC upper-middle-inome ountry UNICEF United Ntions Children s Fund UNICEF SD UNICEF Supply Division V3P vine produt, prie nd prourement WAP weighted verge prie wp whole-ell pertussis YF yellow fever

INTRODUCTION 1 Introdution Informtion ontined in the report ws provided y Memer Sttes of the WHO Europen Region through the nnul Joint Reporting Form (JRF) of WHO nd the United Ntions Children s Fund (UNICEF). Reporting ountries re solely responsile for the ury of the dt provided. Users should exerise ution when interpreting vine prie dt, tking into ount speifi ontexts, irumstnes nd ftors tht my ffet pries pid y individul ountries. The utilized prie mesures im to illustrte prie vritions nd enourge more trnspreny to understnd the underlying uses. They should not e onsidered representtive or set ny prie enhmrks. Glol reognition of the need for vine prie trnspreny In reent yers, onsiderle emphsis hs een pled on the importne of prie trnspreny in vines. The lk of prie trnspreny hs een rised in mny regionl nd glol meetings, nd ffordle priing remins onern for mny ountries. Vine priing is onsiderly less trnsprent thn priing for other lifesving phrmeutils. Efforts hve een mde y few mnufturers to pulish some of the riteri used to estlish priing in some mrkets. However, no single mnufturer reports ll the speifi pries in ll mrkets in whih they sell. The role of inresing trnspreny hs, therefore, een tken up y the purhsing side; oth UNICEF Supply Division (SD) nd the Pn Amerin Helth Orgniztion (PAHO) Revolving Fund hve mde onsiderle improvements to vine prie trnspreny y mking pulilly ville some of the prie rrngements they hve in ple with some mnufturers. Other efforts to improve vine prie trnspreny inlude the Médeins Sns Frontières Right-Shot pulition (1), the GAVI mrket-shping efforts prtiulrly for GAVI grduting ountries (2) nd the WHO Vine, Produt, Prie nd Prourement (V3P) Projet (3). Memer Sttes endorsed the Glol Vine Ation Pln (GVAP) t the Sixty-fifth World Helth Assemly in resolution WHA65.17 (4 5). In the nnul progress report on the Dede of Vines nd Glol Vine Ation Pln, informtion on vine pries t the glol level ws requested (6). This request stems from the onern tht middle-inome ountries (MICs), not supported y donor funding, re prtiulrly hllenged to introdue newer nd more ostly vines. Monitoring GVAP progress, the WHO Strtegi Advisory Group of Experts on immuniztion defined vine ffordility s one of five priority prolems in GVAP implementtion nd lled for greter trnspreny in this re y enourging ountries to exerise more ontrol on vine mrket nd ommit to shring vine priing informtion nd working together to llow evidene-sed ssessment of the sle nd sope of mrket imlnes, nd llow solutions to e developed one the prolems re understood (7). The most ruil spet to ll of these efforts is the willingness of ountries to shre priing dt nd informtion. Strong ommitment for improved trnspreny from the purhsing side is essentil to ensure ontinued improvements in ffordle nd equitle priing to ll ountries.

2 REVIEW OF VACCINE PRICE DATA WHO Europen Region response on vine prie trnspreny The Europen Vine Ation Pln 2015 2020 (EVAP), dopted y the 64th session of the WHO Regionl Committee for Europe on 18 Septemer 2014, sets regionl vision nd gols for immuniztion nd ontrol of vine-preventle diseses from 2015 to 2020 nd eyond. Inresing ess to qulity-ssured vines t ffordle pries is one key omponent to hieving sustinle introdution of new vines. In this ontext, EVAP lls on Memer Sttes to Support prie trnspreny efforts regionlly nd glolly through inresed shring of vine prie informtion. (8). In 2014, the JRF ws used to ollet informtion on the pries of proured vines from Memer Sttes of the WHO Europen Region (Appendix 1). The olleted dt estlished minimum frmework for shring vine priing informtion t the regionl level. It integrtes nd ontriutes to the roder glol efforts imed t inresing trnspreny of vine pries to empower ountries in mking informed vine introdution deisions. This report is designed to onsolidte the olleted dt nd informtion to report k to Memer Sttes. The intention is to ssist ntionl immuniztion progrmme mngers, helth udgeting experts nd experts responsile for vine prourement in essing, understnding nd utilizing ville vine mrket informtion, leding to improved effiieny of vine prourement nd the ility to mke finnilly sustinle, informed deisions on vine prourement nd new vine introdution. The dt olleted in 2014 refers to vines proured during the previous yer, 2013. Twenty-three Memer Sttes sumitted omplete dt (see Appendix 2). This report provides rief overview of the vilility nd trnspreny of vine priing informtion t the ountry level, the vine prourement mehnisms nd the proured vines. In ddition, it inorportes stndrdized tles, displying vine prie informtion for eh of the individul vine produts (see Appendix 3). Vine prie dt provided y individul ountries re expressed in US dollrs (using the World Bnk s verge nnul exhnge rtes for 2013 in Appendix 4) (9) nd rnked from minimum to mximum vlue. Averge prie estimtes (medin vlue nd weighted verge prie (WAP)) were lso lulted. Individul prourement reords inlude some of the vriles expeted to hve potentil impt on prie, inluding the ountry inome group, volume of prourement, produt formultion nd presenttion, delivery terms nd vine prourement mehnism. Limittions of dt The dt provided in this report should not e overnlysed s very few onlusions n e drwn from this limited dt set. In ollting this dt nd the report, every ttempt ws mde to mke the informtion s ler s possile nd to limit misinterprettion of the dt. This is good strt to regionl efforts to improve vine prie trnspreny. However, room for improvement exists in the oming yers. It is hoped nd ntiipted tht over time: the tools for dt olletion will improve nd e simple for the ountries to omplete; the understnding of the importne of providing dt will improve, resulting in ll Memer Sttes in the Region providing these importnt dt nnully; nd the signifine of dt ury, whih llows for improved nlysis nd omprility, will led to improved understnding of the dt nd how they n e utilized.

REPORTING OF VACCINE PRICE DATA 3 Reporting of vine prie dt The olletion nd reporting of vine prie dt is intended to improve mrket trnspreny, redue the symmetry of informtion ville to purhsers nd ssist in mking priing pproprite, fir nd effiient. Of the 53 Memer Sttes in the Region, 47 sumitted their JRF reports for 2013 (see Appendix 2). Twenty-three Memer Sttes (43%) responded to the request to omplete the vine prie setion of the 2013 JRF. Prtil dt on the vine prourement system nd proured produts were provided y seven dditionl Memer Sttes. Therefore the denomintors in the report vry ording to the numer of reporting Memer Sttes ginst speifi inditor. Memer Sttes from ll inome groups shred vine prie dt. The upper-middle- nd high-inome groups showed lower prtiiption rtes in sumitting omplete priing dt 33% (4/12) nd 39% (13/33) ordingly. Tle 1 shows the distriution of ountries reporting vine priing informtion y inome groups, s per the World Bnk s lssifition (10). See Appendix 5 for detiled lssifition of Memer Sttes y inome group. TABLE 1. Reported vine priing dt through the JRF y ountry inome group JRF reports With omplete With inomplete Country inome group (no. of ountries) Sumitted (%) priing dt (%) priing dt (%) High-inome ountry (HIC) (33) 29 13 4 Upper-middle-inome ountry (UMIC) (12) 11 4 2 Lower-middle-inome ountry (LMIC) (6) 5 4 1 Low-inome-ountry (LIC) (2) 2 2 0 Totl (53) 47 (89%) 23 (43%) 7 (13%) Key point Memer Sttes of ll inome groups shred vine prie dt through the nnul JRF reports. The prtiiption rte ws lower mong upper-middle-inome nd high-inome ountries.

4 REVIEW OF VACCINE PRICE DATA Avilility nd trnspreny of vine priing informtion The JRF report inluded three questions imed to ssess the vilility of vine priing informtion t the ntionl level, existing prties of pulishing ntionl vine priing dt in the puli domin, nd the presene of legl provisions tht prevent shring of vine priing informtion. The numer of ountries responding to eh question vried; therefore, different denomintors re used in lultions. Key point Vine priing informtion is widely ville in Memer Sttes of different inome groups; however, these dt re rrely pulished or mde essile. Limited legl restritions provide n opportunity to inrese vine priing trnspreny nd expnd enefits from etter informed deision-mking on vine prourement nd new vine introdution. Of the reporting Memer Sttes, 21 out of 29 (72%) reported tht vine priing informtion ws ville t the ntionl level. Fewer HICs (65%) reported hving vine priing informtion ville ompred to ountries of lower inome groups (83%). Deentrlized vine prourement to suntionl uthorities or outsouring to privte prourement servies in some HICs might explin the differene. Nine out of 25 reporting Memer Sttes (36%) pulish vine priing informtion in the puli domin. Restritions on the ility to shre vine prie informtion were reported y three out of 26 reporting Memer Sttes (12%), ll of whih re HICs. In one se, referene ws mde to speifi legl provisions estlishing the trnspreny restrition, while two others referred to n existing prtie of keeping vine priing dt onfidentil. A summry of vilility nd trnspreny of vine priing informtion is provided in Tle 2. TABLE 2. Avilility nd trnspreny of vine priing informtion y ountry inome group Vine prie informtion Aville t ntionl level Pulished in puli domin Restrited y legl provisions Country inome group Totl no. Totl no. Totl no. (no. of ountries) Yes No of nswers Yes No of nswers Yes No of nswers HIC (33) 11 6 17 4 12 16 3 13 16 UMIC (12) 5 2 7 3 2 5 0 5 5 LMIC (6) 3 0 3 2 1 3 0 3 3 LIC (2) 2 0 2 0 1 1 0 2 2 Totl (53) 21 8 29 9 16 25 3 23 26

VACCINE PROCUREMENT MECHANISMS 5 Vine prourement mehnisms Informtion regrding the use of different vine prourement mehnisms ws provided y 29 Memer Sttes, whih reported purhsing vines through government genies, interntionl prourement genies or omintion of oth. All HICs tht reported through the JRF nd most UMICs utilize ntionl prourement mehnisms operted y government genies. LICs nd LMICs reported enefiting lrgely from the prourement servies provided y interntionl prourement genies suh s UNICEF SD. Tle 3 summrizes the vine prourement mehnisms used. TABLE 3. Prourement mehnisms reported y Memer Sttes in 2013 y ountry inome group Prourement mehnism Ntionl Interntionl prourement y prourement Other, Totl ountry Country inome group government geny geny inluding donors responses HIC (33) 16 0 2 16 UMIC (12) 5 1 1 6 LMIC (6) 2 5 2 5 LIC (2) 1 2 2 2 Totl (53) 24 8 7 29 Eh Memer Stte reported one or more pplile prourement mehnisms.

PROCURED VACCINES 7 Proured vines Informtion on the nmes of the vine produts proured ws sumitted y 30 Memer Sttes nd inluded dt for one or more produts. In totl, 41 different vine produts were proured in 2013. Of these, 13 produts were proured in multiple produt presenttions, inluding pre-filled syringes (PFS) nd single or multidose mpoules nd vils. The list of proured vines is in Fig. 1, rnked y frequeny of the numer of prouring ountries per produt. FIG. 1. Frequeny of proured vines reported y 30 Memer Sttes VACCINES Typhoid-heptitis A TdP-IPV TBE MMRV Men AC JE_Intd JE HiMenC YF MR Mesles HepAHepB DTP-Hi Typhoid fever Influenz_peditri Men ACWY Pneumo_ps HepA DTP Vriell Rotvirus MenC_onj TT Hi DTwP-Hi-HepB DTP-Hi-HepB-IPV TdP IPV HepB_dult DTwP OPV Influenz_dult HPV DTP-IPV DT PCV DTP-Hi-IPV Td BCG HepB_peditri MMR 1 1 1 1 1 1 1 1 2 2 2 2 2 3 3 4 5 6 6 7 7 7 8 8 8 8 9 10 11 11 13 13 13 13 14 15 17 23 24 0 5 10 15 20 25 30 26 29 41 different vine produts were proured in 2013. NO. OF COUNTRIES

8 REVIEW OF VACCINE PRICE DATA BCG: ille Clmette Guérin (tuerulosis) vine; DT: diphtheri nd tetnus toxoids, peditri formultion; DTP: DT nd ellulr pertussis vine, peditri formultion; DTP-Hi: DTP nd Hemophilus influenze type vine; DTP-Hi-HepB-IPV: DTP, Hemophilus influenze type, heptitis B nd intivted poliovirus vine; DTP-Hi-IPV: DTP, Hemophilus influenze type nd intivted poliovirus vine; DTP-IPV: DTP nd intivted poliovirus vine; DTwP: diphtheri nd tetnus toxoids nd whole-ell pertussis vine, peditri formultion; DTwP-Hi-HepB: DTwP, Hemophilus influenze type vine nd heptitis B vine; HepA: heptitis A vine; HepAHepB: heptitis A nd heptitis B vine; HepB_dult: heptitis B vine, dult formultion; HepB_peditri: heptitis B vine, peditri formultion; Hi: Hemophilus influenze type ; HiMenC: Hi nd meningool serogroup C vine; HPV: humn ppillomvirus; Influenz_dult: sesonl influenz vine, dult formultion; Influenz_peditri: sesonl influenz vine, peditri formultion; IPV: intivted poliovirus vine; JE: Jpnese enephlitis live ttenuted vine; JE_intd: Jpnese enephlitis intivted vine; Men AC: meningool AC vine; Men ACWY: meningool ACWY vine; MenC_onj: meningool C onjugte vine; MMR: mesles, mumps nd ruell vine; MMRV: mesles, mumps, ruell nd vriell vine; MR: mesles ruell vine; OPV: orl poliovirus vine; PCV: pneumool onjugte vine; Pneumo_ps: pneumool polyshride vine; TBE: tik-orne enephlitis; Td: tetnus nd diphtheri vine, dult/dolesent formultion; TdP: Td nd ellulr pertussis vine, dult/dolesent formultion; Tdp-IPV: TdP nd IPV, dult/dolesent formultion; TT: tetnus toxoid; Typhoid-heptitis A: typhoid fever nd heptitis A vine; YF: yellow fever Aross the 30 reporting Memer Sttes, MMR ws the most ommonly proured vine, followed y HepB_peditri, BCG nd Td vines. Comintions of diphtheri tetnus pertussis- (DTP) nd IPV-ontining vines vried etween ountries: the most ommon proured produt ws pentvlent DTP-Hi-IPV (17 ountries), followed y DTP-IPV (13 ountries). Of the more reently introdued vines, PCV nd HPV vines were proured in 15 nd 13 Memer Sttes, respetively. Rotvirus vine ws reported y 7 nd vriell vine y 6 Memer Sttes. Vines were proured in vrious presenttions, from single dose to 20 doses per primry ontiner (Tle 4). Most vines (70%) were in single dose presenttions, followed y 10 dose presenttions (21%) nd 20 dose presenttions (4%). BCG nd OPV vines were only in 10 or 20 dose presenttions. Multidose presenttions were represented minly y trditionl ntigens nd omintions: DT, DTwP, heptitis B, MMR, Td nd TT nd vines. TABLE 4. Frequeny of proured vine presenttions Vine presenttion Vine presenttion (doses/primry ontiner) (doses/primry ontiner) Vine produt 1 2 5 10 20 Vine produt 1 2 5 10 20 BCG 15 11 Mesles 2 1 DT 3 1 9 Men AC 1 DTP 5 Men ACWY 2 DTP-Hi 1 MenC_onj 5 DTP-Hi-HepB-IPV 7 MMR 22 6 4 DTP-Hi-IPV 17 MMRV 1 DTP-IPV 13 MR 2 DTwP 4 1 8 OPV 13 4 DTwP-Hi-HepB 10 2 1 Pneumo_ps 3 HepA 5 PCV 17 HepAHepB 3 Rotvirus 9 HepB_dult 8 1 TBE 2 HepB_peditri 23 1 3 Td 10 2 11 Hi 6 TdP 7 HiMenC 1 Tdp-IPV 1 HPV 13 TT 2 2 3 Influenz_dult 14 Typhoid fever 1 1 Influenz_peditri 3 Typhoid-heptitis A 1 IPV 10 Vriell 6 JE 1 YF 1 JE_intd 1 1 dose presenttion inludes one-dose mpoules, vils or vine prefilled syringes.

MANUFACTURER BASE OF PROCURED VACCINES 9 Mnufturer se of proured vines A ompetitive supply environment represents n importnt driver to optimizing vine pries: s ompetition inreses nd supply is suffiient to meet demnd, pries n derese to sustinle plteu. Tle 5 lssifies vine produts into three groups limited, moderte or lrge sed on the numer of mnufturers of proured vines, s reported y prtiipting Memer Sttes. TABLE 5. Distriution of proured vine produts y numer of vine mnufturers Mnufturer se Limited Moderte Lrge (1 3 mnufturers) (3 4 mnufturers) ( 5 mnufturers) Vine No. of Vine No. of Vine No. of mnufturers mnufturers mnufturers HepAHepB 1 Influenz_dult 3 DTwP 5 HiMenC 1 Influenz_peditri 3 BCG 6 JE 1 IPV 3 TT 6 JE_intd 1 Mesles 3 DT 7 Men ACWY 1 MenC_onj 3 HepB_peditri 7 MMRV 1 PCV 3 Td 13 MR 1 TdP 3 TBE 1 Typhoid fever 3 Typhoid-heptitis A 1 DTwP-Hi-HepB 4 YF 1 HepB_dult 4 DTP 2 MMR 4 DTP-Hi 2 OPV 4 DTP-Hi-HepB-IPV 2 DTP-Hi-IPV 2 HepA 2 Hi 2 HPV 2 Pneumo_ps 2 Rotvirus 2 Tdp-IPV 2 Vriell 2 These dt do not represent the numer of glolly ville mnufturers, nor does it imply similr qulity stndrds for eh mnufturer reported. The numer of mnufturers ville to supply vines in eh Memer Stte my differ due to mrket uthoriztion nd ntionl regultory requirements. Furthermore, the mnufturers reported s hving supplied vines my not represent ll those ville in eh Memer Stte.

10 REVIEW OF VACCINE PRICE DATA More thn hlf of the proured vines (22) were only supplied y one or two mnufturers. Among these re new nd underused vines, suh s rotvirus, PCV, HPV, ellulr pertussis (P) nd IPV-sed vine omintions. A moderte mnufturer se ws reported for 12 produts, inluding ommonly used OPV, IPV, MMR nd DTwP-Hi-HepB vines. The list of vines with helthy ompetitive mnufturer se ws reltively short nd inluded trditionl vines. Key point Memer Sttes re enourged to review lol versus interntionl suppliers nd seek opportunities to optimize lolly ville ompetition. A restrited mnufturer se my limit the ility of Memer Sttes to otin n optimum vine prie nd my inrese the supply hin unertinty, oth in terms of gining ess to vine supply (i.e. willingness of the supplier to supply the produt to speifi mrket) nd gining uninterrupted supply of ontrted produts (i.e. in se of mnufturing or supply disruptions). The dt olletion tool did not provide the opportunity to review other ftors tht my disourge or limit the ompetition t the ountry level, suh s regultory requirements (i.e. mrket uthoriztion fee poliies, dossier review timing nd requirements, lol lnguge nd representtion requirements), progrmmti requirements (produt formultion nd presenttion, vine vil monitors), s well s prourement poliies nd ontrtul terms (i.e. long-term foresting, nnul versus multiyer ontrting, pyment mehnisms nd timelines, dditionl/undled servies, et.). Memer Sttes re enourged to review lol versus interntionl suppliers nd seek opportunities to optimize lolly ville ompetition. A vine mrket review needs to inform progrmmti deisions on dopting speifi produt formultions or presenttions to ensure ess to qulity produts t n ffordle prie. WHO provides system for the prequlifition of vines to determine the eptility, in priniple, of vines from different soures for supply to UNICEF nd other United Ntions genies tht purhse vines (11). The list of WHO prequlified vines nd their mnufturers s of 1 Jnury 2015 is in Appendix 6; the list is ontinuously updted (12). Furthermore, informtion regrding vines registered with the Europen Mediines Ageny n e found t its wesite (13).

REPORTED VACCINE PRICES 11 Reported vine pries Vine priing is omplex nd multidimensionl sujet. A numer of importnt demnd side (purhsing) ftors my influene the vine prie suh s prourement mehnism, sle of prourement, prourement methodology nd ontrtul terms (suh s pyment nd delivery terms). Sine ountries reported pries using different prourement prmeters nd dt were not ville or insuffiient to disggregte ording to these prmeters, the min purpose of this report is to show vrition of pries nd some of the ftors potentilly influening pries. Prie informtion tles per vine produt provide ountry-speifi prmeters olleted for eh proured vine (see Appendix 3). The tles re stndrdized. Vine prie dt were provided y individul ountries, nd pries re expressed in US dollrs (using the World Bnk s verge nnul exhnge rtes for 2013 (9)) nd rnked from minimum to mximum vlue. Individul prourement reords inlude some of the vriles expeted to hve potentil impt on prie, inluding the ountry inome group, volume of prourement, produt formultion nd presenttion, delivery terms nd vine prourement mehnism. Country nmes nd mnufturers re not inluded in this report, ssuming tht suh informtion should not represent n essentil priing driver. Where Memer Sttes reported prourement through UNICEF SD nd provided prie pid, this prie is reorded s reported nd my differ from pries reported y UNICEF SD (14). Quntittive prie estimtes were lso lulted. However, the quntittive mesures used do not ount for the heterogeneity of individul prourement ftors. In some instnes, this leds to underestimting or overestimting the vine pries. Therefore, the utilized quntittive mesures nd the susequent results should not e onsidered representtive ut rther illustrtive. Key point The utilized prie mesures im to illustrte prie vritions nd enourge more trnspreny to understnd the underlying uses. They should not e onsidered representtive or set ny prie enhmrks. Minimum nd mximum prie vlues for speifi produt define the oserved rnge of prie vrition. The verge mesures of prie in this nlysis inlude the medin prie nd the WAP. WAP represents the verge prie weighted y the volume of eh purhsed produt. WAP is sensitive, in prtiulr, to the prie pid for lrger volumes. The medin prie represents mid-rnge vine prie vlue ross reported prourements, is not dependent on extreme prie vlues nor on proured volumes, nd would represent etter the prie otined during n verge prourement regrdless of the proured volume. A lrge differene etween WAP nd the medin prie indites skewed distriution of the prie pid for vine produt, whih ould e used y multiple ftors. Dt interprettion would require, in ddition, detiled review of individul prourement ontext tht is eyond the sope of the dt olletion mehnism used in this report. Tle 6 summrizes the quntittive prie dt nd displys importnt prie vritions for most of the proured vine produts.

12 REVIEW OF VACCINE PRICE DATA TABLE 6. Minimum, mximum, medin nd verge pries reported y vine produt Vine prie per dose (US$) No. of Vines with rerported rerported prie dt prourements Minimum Mximum Medin WAP DT-IPV 1 8.10 8.10 N/A N/A Influenz_peditri 1 5.46 5.46 N/A N/A Men AC 1 17.62 17.62 N/A N/A YF 1 16.23 16.23 N/A N/A OPV 12 0.14 7.67 0.22 0.26 DTwP 8 0.10 3.08 0.38 1.03 BCG 18 0.06 12.50 0.39 0.29 MR 2 0.52 0.60 0.56 0.58 TT 7 0.08 4.02 0.61 0.83 Td 20 0.10 22.29 1.57 4.34 DT 10 0.11 16.51 1.81 0.36 Mesles 3 1.44 5.98 2.09 1.80 DTwP-Hi-HepB 11 2.14 2.95 2.70 2.39 Rotvirus 6 2.46 15.57 2.73 9.80 HepB_peditri 21 0.16 11.95 3.41 1.48 Influenz_dult 11 2.73 14.29 4.62 4.55 MMR 26 0.98 14.38 6.56 5.06 IPV 9 4.94 12.94 7.21 6.32 Typhoid fever 2 4.22 13.88 9.05 4.24 DTP 7 2.65 22.58 9.15 5.58 Hi 6 4.03 19.26 9.42 6.55 HepB_dult 8 1.11 19.58 11.71 7.19 TdP 8 10.42 24.04 12.67 11.23 Pneumo_ps 3 10.38 22.39 13.68 10.40 Men ACWY 3 12.19 42.76 14.21 41.48 DTP-IPV 9 8.72 30.23 14.68 10.20 DTP-Hi-IPV 12 7.98 44.49 17.20 13.16 MenC_onj 5 10.76 28.88 19.19 18.76 HepA 6 7.45 34.26 23.21 7.91 HepAHepB 3 26.96 45.16 36.57 36.69 Vriell 5 17.35 50.46 41.17 19.87 HPV 11 20.94 93.40 41.38 36.86 DTP-Hi 2 21.21 41.67 43.39 37.21 DTP-Hi-HepB-IPV 9 22.85 59.15 43.39 37.21 PCV 15 3.53 66.28 43.96 35.12 Sorted y medin prie N/A: not pplile Generlly, new nd underused vines show signifintly higher verge pries nd prie vritions ompred to trditionl vines, suh s BCG, OPV, DTP nd MMR. Prourement ontext, progrmmti nd produt detils re essentil in understnding the nture of the vritions. For exmple, in the se of pneumool onjugte vines, two ountries enefit from susidized donor prie, whih is onsiderly lower thn the unsusidized pries. However, in the se of mny other vines (i.e. DTP-Hi-HepB-IPV, DTP-Hi-IPV) there re no susidy mehnisms tht would influene the prie vrition. A prtiulr hllenge is interpreting the prie of rotvirus vine, where oth prie susidy mehnisms (to ountries enefiting from GAVI support) nd different primry vintion shedules re pplied depending on the vine produt used (2 versus 3 doses per shedule). Furthermore, some vines, while preventing the sme diseses, my hve different ntigen formultions, i.e. pneumool onjugte vine (PCV10 versus PCV13) 1 nd HPV vine (qudrivlent versus ivlent vine). Prie informtion tles in Appendix 2 provide dditionl informtion to llow the reder to mke n informed omprison. 1 PCV 10 (or PCV 13) vlent inludes ntigens from the 10 (or 13) most ommon serotypes using invsive pneumool disese mong hildren.

REPORTED VACCINE PRICES 13 Country inome level nd vine pries pid Tiered priing is form of prie differentition: hrging different pries, in different mrkets, for the sme produt. Generlly, vine mnufturers dopt their own individul poliies to hrge higher vine pries in welthier ountries while keeping pries lower for ountries tht nnot fford the prie on the open mrket nd for donor supported prourement. Two produts re nlysed further: heptitis B vine widely implemented produt with lrge supplier se nd HPV vine, reltively new produt with limited supplier se. The dt olleted show tht high vine pries re exhiited not only in HICs ut lso in MICs. Fig. 2 2 show prie vritions of heptitis B (peditri dose) nd HPV vines ross ountries of different inome groups. Heptitis B vine is widely used produt, nd its prourement nd pries were reported y ountries of ll inome groups. In ontrst, HPV vine pries were reported only y HICs nd UMICs. The figures disply the medin vlue, the 25 75-perentile (interqurtile) rnge, s well s minimum nd mximum prie vlues pid y Memer Sttes. FIG 2A. HepB peditri vine prie y ountry inome group FIG 2B. HPV vine prie y ountry inome group 14 VACCINE PRICE (US$) Mximum 100 VACCINE PRICE (US$) 12 10 75th perentile Medin 25th perentile 80 8 Minimum 60 6 40 4 20 2 0 HICs UMICs LMICs LICs 0 HICs UMICs The reported dt show tiered priing for the heptitis B vine; the prie inrese follows the inome level of the Memer Sttes. The sitution is very different, however, in the se of the HPV vine, new nd underused vine. MICs pid onsiderly higher prie thn HICs. Why did MICs py higher prie for new nd initilly very expensive vine? This rises n importnt prie equity issue tht needs to e ddressed in the ontext of Key point Compred to HICs, UMICs pid higher prie for HPV vines, rising prie equity nd sustinility onerns.

14 REVIEW OF VACCINE PRICE DATA rehing EVAP ojetives. The ost effiieny of introduing new vines is key onern, nd unsustinl high vine pries my prevent Memer Sttes from deiding to introdue new vines. High vrition of vine pries within inome groups is oserved for oth vines, whih indites potentil opportunities to improve prourement effiieny. Vine prourement volumes nd prie Did the prourement of lrger vine volumes result in lower pries? In generl, the lrger the volumes of proured vine, the lower the pries were. This trend is vlid for oth the proured HepB_peditri nd HPV vines, lthough importnt prie vritions for the sme proured volumes re seen s well. Fig. 3 3 depit the pries pid y Memer Sttes per purhsed volume. FIG 3A. HepB peditri vine prie/dose y proured volume nd ountry inome group FIG 3B. HPV prie/dose y proured volume nd ountry inome group 12 VACCINE PRICE (US$) VACCINE PRICE (US$) 100 10 8 6 HICs UMICs LMICs LICs 80 60 HICs UMICs 4 40 2 20 0 0 0 200 000 400 000 600 000 800 000 0 100 000 200 000 300 000 400 000 PROCURED VOLUME (DOSES) PROCURED VOLUME (DOSES) As expeted, LICs nd LMICs pid the lowest prie per volume for HepB_peditri vines. All ut one UMIC fit in the prie/volume trend s well. HICs pid the highest heptitis B vine pries, following the trend of deresing prie per purhsed volume. By ompring similr proured volumes, Fig. 3 shows tht ll three HPV prie points reported y UMICs re higher thn pries reported for HICs. Understnding why UMICs ould not hieve t lest the sme or lower prie per volume ompred to HICs nd ddressing prourement ineffiienies re key to mking the new vines more ffordle nd equitle. Key point Compred to HICs, UMICs ould not hieve t lest the sme or lower prie per volume in prouring HPV vines.

REPORTED VACCINE PRICES 15 Vine presenttion nd prie Vine presenttion is nother importnt prie driver. In generl, pries per dose re lower with the inresing presenttion size of produt. The pries of two produts ville in vrious presenttions (HepB nd MMR) re nlysed further. Fig. 4 4 show tht for oth HepB nd MMR vines, the prie of 10 dose presenttions re lower thn 1- or 2-dose presenttions. However, 10-dose presenttions were proured only y LICs nd LMICs; UMICs proured 1- nd 2-dose presenttions, nd HICs proured exlusively single-dose presenttions. Fig. 4 4 show, in numer of situtions, tht UMICs pid higher prie per dose for the sme vine presenttion ompred to some HICs. Both HepB nd MMR vines hve high vrition of vine prie within the sme presenttion. FIG 4A. HepB_peditri vine prie/dose y vine presenttion nd ountry inome group FIG 4B. MMR prie/dose y vine presenttion nd ountry inome group VACCINE PRICE (US$) VACCINE PRICE (US$) 12 10 1 dose/vil 2 doses/vil 10 doses/vil 25 20 1 dose/vil 2 doses/vil 10 doses/vil 8 15 6 10 4 2 5 0 0 HICs UMICs LMICs LICs HICs UMICs LMICs LICs Key point Compred to HICs, UMICs fvor single dose presenttions nd often pid higher vine prie for the sme presenttion. Vine formultion nd prie Pries vry y produt formultion s well; for exmple, P-ontining vines ontinue to e signifintly more expensive thn whole-ell pertussis (wp) ontining produts. Aording to WHO, oth P-ontining nd wp-ontining vines hve exellent sfety reords. The mrginl enefit of hnging from wp-ontining to P-ontining vines should therefore e refully weighed ginst the issue of ffordility (15). The limited supplier se in P-ontining vines, ompred to the moderte or lrge supplier ses for wp-ontining produts (Tle 5), would lso dvntge wp-ontining vines in terms of gining prourement effiienies nd seuring n uninterrupted supply.

16 REVIEW OF VACCINE PRICE DATA Tle 7 shows tht prourement of P- nd wp-ontining vines vry y inome group; the higher the inome group, the higher the shre of proured P-ontining vines. In prtiulr, LICs reported prouring exlusively wp formultions; LMICs reported P formultions in two out of 11 prourements; UMICs reported lrger shre of P-ontining vines (10 out of 16 proured produts); nd HICs reported prourement of P-ontining vines in ll ut one se. TABLE 7. Frequeny of proured formultions of pertussis-ontining vines y ountry inome group Vine HICs UMICs LMICs LICs TOTAL DTP 5 1 2 8 DTP-Hi 2 2 DTP-Hi-HepB-IPV 6 3 9 DTP-Hi-IPV 14 4 18 DTP-IPV 12 2 14 DTwP 1 4 4 2 11 DTwP-Hi-HepB 2 5 6 13 Totl P-ontining vines 39 10 2 0 51 Totl wp-ontining vines 1 6 9 8 24 Equivlent P nd wp produts were reported for one type of omined vine DTP. Other reported vine omintions vry y their ntigens. Fig. 5 5 ompre pries for two types of produts; one ontins three ntigens (DTwP versus DTP) nd the other ontins five ntigens (DTwP-Hi-HepB versus DTP-Hi-IPV). Fig. 5 shows tht DTwP pries were low with little vrition, with the exeption of the prie pid y one HIC for domesti wp produt. For DTP, pries were signifintly higher nd showed lrge vrition. The prie pid y LMICs nd UMICs for DTP rehed the level pid y HICs. FIG 5A. DTwP nd DTp vine prie y ountry inome group FIG 5B. DTwP Hi HepB nd DTP Hi IPV vine prie y ountry inome group VACCINE PRICE (US$) VACCINE PRICE (US$) 25 DTwP DTP 50 45 DTwP-Hi-HepB DTP-Hi-IPV 20 40 35 15 30 25 10 20 15 5 10 5 0 0 HICs UMICs LMICs LICs HICs UMICs LMIs LICs

REPORTED VACCINE PRICES 17 A similr pttern is oserved for pentvlent vine omintions in Fig 5. DTwP-Hi-HepB ws introdued in LMICs with GAVI support nd ws proured minly through UNICEF SD. Vine pries were low, with little vrition, refleting minly the use of different vine presenttions rther thn inome group differenes. DTP-Hi-IPV pries were onsiderly higher, with lrge vritions oth etween nd within inome groups. UMICs pid generlly lower pries; however, in numer of ses, the pries rehed or surpssed those pid y some HICs. Key point Pries of vine formultions vry. The ost implitions of speifi formultion hoie need to e refully onsidered ginst ttined enefits. It should e noted tht P produt omintions my ring omprtive dvntge y providing roder rnge of ntigens in one produt, inluding IPV, whih is not ville in wp-ontining vines. These gin importne in the ontext of the Polio Erdition nd Endgme Strtegi Pln 2013 2018 (16), whih reommends introdution of t lest one dose of IPV into routine immuniztion shedules (17). It is eqully true, however, tht stndlone IPV produts re ville t muh lower pries nd ould e dministered onomitntly with wp-omined produts. The GAVI Alline s deision to support the introdution of stndlone IPV in GAVI-eligile nd grduting ountries ould represent ost-effiient exmple of produt formultion hoie (18).

18 REVIEW OF VACCINE PRICE DATA WHO s V3P pltform WHO estlished the V3P pltform to ollet detiled nd omprehensive vine prie informtion from ountries nd mke it pulily ville (3). In doing so, V3P prtiiptes in glol reporting on vine pries to further prtners efforts on improving prie trnspreny nd to inform ontinued disussion on ffordle priing. The informtion olleted y V3P is used to monitor glol prie nd prie trnspreny trends for the GVAP vine prie report tht is prt of the GVAP monitoring. (4). The V3P pltform is one-stop-shop wesite tht inludes: prie dtse olleting nd disseminting dt on vine pries nd key prourement ftors; repository of V3P-speifi doumenttion, nlyses s well s key reports nd updtes; nd gtewy with links to other vine nd immuniztion relted soures. Memer Sttes re enourged to shre nd enefit from more detiled informtion y essing the V3P dtse diretly (19). A ntionl fol point to shre priing informtion shll e nominted in dvne nd detils ommunited to WHO in order to grnt ess to the input tool of the V3P dtse. Alterntively, ountries n lso hoose to shre their vine prie dt through their JRF. Key point WHO s V3P pltform ollets detiled nd omprehensive vine prie informtion from ountries nd mkes it pulily ville through its online dtse. Appendix 7 provides dditionl soures for pulished vine priing dt, whih n e essed through the V3P resoure gtewy (20).

20 REVIEW OF VACCINE PRICE DATA Referenes 2 1. The right shot: ringing down rriers to ffordle nd dpted vines, 2nd edition. Genev: Médeins Sns Frontières; 2015 (www.msfess.org/rightshot2). 2. Mking vines more ffordle. In: GAVI The Vine Alline [wesite]. Genev: GAVI Alline; 2015 (http://www.gvi.org/out/gvis-usiness-model/mking-vines-ffordle/). 3. The Vine Produt, Prie nd Prourement (V3P) Projet. In: World Helth Orgniztion [wesite]. Genev: World Helth Orgniztion; 2015 (http://www.who.int/immuniztion/progrmmes_systems/prourement/v3p/en/). 4. Glol Vine Ation Pln 2011 2020. Genev: World Helth Orgniztion; 2013 (http://www.who.int/immuniztion/glol_vine_tion_pln/en/). 5. World Helth Assemly resolution WHA65.17. Glol vine tion pln. Sixty-fifth World Helth Assemly, Genev, 21 26 My 2012. Genev: World Helth Orgniztion; 2012 (http://pps.who.int/g/ewh/pdf_files/wha65/a65_r17-en.pdf). 6. Glol vine tion pln. Report y the Seretrit, 22 Mrh 2013. Provisionl gend item 16.1 to Sixty-sixth World Helth Assemly, Genev, 20 28 My 2013. Genev: World Helth Orgniztion; 2013 (http://pps.who.int/g/ewh/pdf_files/wha66/a66_19-en.pdf). 7. Meeting of the Strtegi Advisory Group of Experts on immuniztion, Otoer 2014 onlusions ndreommendtions. Wkly Epidemiol Re. 2014;50(89):561 76 (http://www. who.int/wer/2014/wer8950.pdf?u=1). 8. Europen Vine Ation Pln 2015 2020. Copenhgen: WHO Regionl Offie for Europe; 2014 (http://www.euro.who.int/en/helth-topis/disese-prevention/vines-nd-immuniztion/pulitions/2014/europen-vine-tion-pln-20152020). 9. Offiil exhnge rte (LCU per US$, period verge) [online dtset]. Wshington, DC: World Bnk; 2015 (http://pi.worldnk.org/ountries/inditors/dpanuslcu?per_ pge=30000∓dte=2005:2013). 10. Gross ntionl inome per pit 2012, Atls method nd PPP. Wshington, DC: World Bnk; 2013 (http://dtnk.worldnk.org/dt/downlod/gnipc.xls, essed 23 Septemer 2013). 11. A system for the prequlifition of vines for UN supply. In: World Helth Orgniztion [wesite]. Genev: World Helth Orgniztion; 2015 (http://www.who.int/immuniztion_ stndrds/vine_qulity/pq_system/en/). 12. WHO prequlified vines [online dtset]. Genev: World Helth Orgniztion; 2015 (http://www.who.int/immuniztion_stndrds/vine_qulity/pq_vine_list_en/en/). 13. Europen Mediines Ageny [wesite]. London: Europen Mediines Ageny; 2015 (http:// www.em.europ.eu). 14. Vine prie dt. In: UNICEF [wesite]. Copenhgen: United Ntions Children s Fund; 2015 (http://www.unief.org/supply/index_57476.html). 2 Wesites essed 3 Mrh 2015 unless noted otherwise.

REFERENCES 21 15. Revised guidne on the hoie of pertussis vines: July 2014. Wkly Epidemiol Re. 2014;30(89):337 40 (http://www.who.int/wer/2013/wer8930.pdf?u=1). 16. Polio Erdition nd Endgme Strtegi Pln 2013 2018. Genev: World Helth Orgniztion; 2013 (http://www.polioerdition.org/resourelirry/strtegyndwork. spx). 17. Polio vines: WHO position pper, Jnury 2014. Wkly Epidemiol Re. 2014;9(89):73 92 (http://www.who.int/wer/2014/wer8909.pdf). 18. Intivted polio vine support. In: GAVI The Vine Alline [wesite]. Genev: GAVI Alline; 2015 (http://www.gvi.org/support/nvs/intivted-polio-vine/). 19. V3P we pltform. Prie dtse [online dtse]. Genev: World Helth Orgniztion; 2015 (http://who.int/immuniztion/progrmmes_systems/prourement/v3p/pltform/module1/v3pdtentry/en/). 20. Resoure gtewy V3P. In: World Helth Orgniztion [wesite]. Genev: World Helth Orgniztion; 2015 (http://www.who.int/immuniztion/progrmmes_systems/prourement/v3p/pltform/module3/en/).

APPENDIX 1 23 Appendix 1. JRF templte used to ollet vine priing dt for 2013 2B1. Is informtion on pries of vines, proured for the ntionl immuniztion progrmme, ville t the ntionl level in your ountry? If no, plese explin why vine prie Informtion is not ville t the ntionl level. 2B2. Is informtion on pries of vines, proured for the ntionl immuniztion progrmme, pulished on puli domin in your ountry? If yes, plese indite the domin where ntionl vine prie informtion n e essed. 2B3. Are there legl provisions restriting shring informtion on pries of vine, proured for the ntionl immuniztion progrmme, in your ountry? If yes, plese provide detils on provisions tht do restrit shring vine prie informtion. A B C D E F G H I J K L Vine/ Supplies Vil size (doses per vil) Nme of mnufturer Country of mnufture Whih Totl no. geny of proured proured doses the vine (units for syringes nd sfety oxes) Curreny Contrted or quoted terms of delivery Totl ost pid ording to quoted Inoterm FCA prie per dose (FCA ost/no. of doses) DDP prie per dose (DDP ost/no. of doses) Notes

24 REVIEW OF VACCINE PRICE DATA Appendix 2. Memer Sttes reporting sttus of vine priing dt in the nnul WHO/UNICEF JRF, 2013 TABLE A2.1. Reporting sttus Country Reporting sttus Country Reporting sttus Alni Complete Lithuni Inomplete Andorr Complete Luxemourg Not reported Armeni Complete Mlt Not reported Austri Missing JRF Mono Missing JRF Azerijn Not reported Montenegro Not reported Belrus Inomplete Netherlnds Complete Belgium Not reported Norwy Inomplete Bosni nd Herzegovin Missing JRF Polnd Complete Bulgri Not reported Portugl Complete Croti Complete Repuli of Moldov Complete Cyprus Not reported Romni Complete Czeh Repuli Not reported Russin Federtion Not reported Denmrk Not reported Sn Mrino Complete Estoni Complete Seri Not reported Finlnd Complete Slovki Complete Frne Not reported Sloveni Complete Georgi Inomplete Spin Complete Germny Not reported Sweden Not reported Greee Not reported Switzerlnd Not reported Hungry Not reported Tjikistn Complete Ielnd Complete The former Yugoslv Repuli of Medoni Complete Irelnd Missing JRF Turkey Complete Isrel Inomplete Turkmenistn Inomplete Itly Missing JRF Ukrine Missing JRF Kzkhstn Complete United Kingdom Not reported Kyrgyzstn Complete Uzekistn Complete Ltvi Complete Inomplete indites return of the JRF form with prtil dt filled out. Missing JRF indites tht no JRF form ws sumitted y the ountry. Not reported indites tht the JRF form ws returned with empty vine prie templte. For more detils plese see the setion on reporting of vine prie dt.

APPENDIX 3 25 Appendix 3. Country-speifi vine prie dt y individul produt Prie informtion tles (Tles A3.1 A3.35) provide ountry-speifi prmeters olleted for eh proured vine. The detils re in the hpter Reported vine pries. Vine pries re expressed in US dollrs using the World Bnk s verge nnul exhnge rtes for 2013 (1) nd ountry inome groups re sed on gross ntionl inome (GNI) per pit dt from the World Bnk (2). Where Memer Sttes reported prourement through UNICEF SD nd provided prie pid, this prie is reorded s reported nd my differ from pries reported y UNICEF SD (3). The ppendix tles use the following suset of Inoterms 2010, set of rules pulished y the Interntionl Chmer of Commere, whih define the responsiilities of sellers nd uyers for the delivery of goods under sles ontrts (4): ost insurne nd freight (CIF) rrige nd insurne pid to (CIP) delivered t ple (DAP) delivered duty pid (DDP) ex works (EXW) free rrier (FCA).

26 REVIEW OF VACCINE PRICE DATA TABLE A3.1. BCG No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LMIC 20 UNICEF SD 44 000 CIF 0.06 Inludes 10% vlue-dded tx(vat) & 3% exise tx 2 LMIC 20 UNICEF SD 225 200 CIF 0.07 3 LMIC 20 UNICEF SD 800 000 FCA 0.07 4 LIC 20 UNICEF SD 420 000 FCA 0.10 5 LMIC 20 UNICEF SD 44 000 CIF 0.14 Inludes 10% VAT & 3% exise tx 6 LIC 20 UNICEF, 330 000 FCA 0.14 WHO or PAHO 7 LMIC 20 Government geny 200 000 DDP 0.19 8 UMIC 10 Government geny 15 000 000 DDP 0.20 9 HIC 10 Government geny 57 000 FCA 0.37 10 UMIC 20 Government geny 1 329 500 DDP 0.41 11 HIC 20 Government geny N/D DDP 0.56 12 UMIC 10 Government geny 40 000 DDP 0.62 13 HIC 10 N/D 6 000 CIP 0.62 14 HIC 10 Government geny 50 150 DDP 1.37 15 HIC 10 Government geny 43 530 DDP 1.39 DDP servie points 16 UMIC 20 Government geny 418 400 N/D 1.53 17 HIC 10 Government geny 137 000 N/A 4.58 In-ountry prodution 18 HIC 10 Government geny 30 877 DDP 12.50 Medin 0.39 WAP 0.29 N/A: not pplile; N/D: no dt or informtion ville; PAHO: Pn Amerin Helth Orgniztion. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.2. dt No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LMIC 10 UNICEF SD 24 000 CIF 0.11 Inludes 10% VAT & 3% exise tx 2 LIC 10 UNICEF SD 160 000 FCA 0.12 3 LIC 10 Government geny 220 000 FCA 0.13 4 LMIC 10 Government geny 48 000 DDP 0.24 5 UMIC 10 Government geny 10 000 DDP 0.46 6 HIC 1 Government geny 200 DDP 3.15 DDP servie points 7 UMIC 1 Government geny 20 000 DDP 3.44 8 HIC N/D Government geny 250 EXW 5.58 9 HIC 10 Government geny 800 FCA 14.47 10 HIC 1 Government geny 1 495 N/A 16.51 In-ountry prodution Medin 1.81 WAP 0.36 N/A: not pplile; N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue.

APPENDIX 3 27 TABLE A3.3. DTP No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 HIC 1 Government geny 523 000 CIF 2.65 2 LMIC 1 UNICEF SD 20 110 CIF 8.00 3 LMIC 1 UNICEF SD 48 000 CIF 8.00 4 HIC 1 Government geny N/D DDP 9.15 5 UMIC 1 Government geny 373 200 DDP 9.21 6 HIC N/D Government geny 20 EXW 17.50 7 HIC 1 Government geny 900 N/D 22.58 Entry tx free Medin 9.15 WAP 5.58 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.4. DTP-Hi No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 HIC 1 Government geny 98 631 DDP 21.21 2 HIC N/D Government geny 10 EXW 41.67 Medin 31.44 WAP 21.22 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.5. DTP-Hi-HepB-IPV No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 UMIC 1 Government geny 205 000 N/D 22.85 2 UMIC 1 N/D 740 900 DDP 30.73 3 UMIC 1 Government geny 177 000 N/D 32.76 4 HIC N/D Government geny 1 025 768 FCA 38.06 Tx free, 2-yer prourement 5 HIC 1 Government geny 73 858 DDP 43.39 DDP servie points 6 HIC 1 Government geny 720 000 DDP 44.76 7 HIC 1 Government geny 161 388 DAP 47.87 Phrmy prie 8 HIC 1 Government geny 2 000 N/D 53.78 Entry tx free 9 HIC N/D Government geny 800 EXW 59.15 Medin 43.39 WAP 37.21 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue.

28 REVIEW OF VACCINE PRICE DATA TABLE A3.6. DTP-Hi-IPV No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 UMIC 1 Government geny 5 000 000 DDP 7.98 2 UMIC 1 Government geny 705 098 DDP 13.44 3 HIC 1 Government geny 14 490 N/D 13.55 4 HIC 1 N/D 93 980 DAP 13.94 5 HIC 1 Government geny N/D DDP 15.03 6 UMIC 1 Government geny 471 700 N/D 16.56 7 HIC 1 Government geny 181 830 DDP 17.85 8 HIC 1 Government geny 64 000 FCA 20.44 9 HIC 1 Government geny 288 759 DDP 23.17 10 HIC N/D Government geny 1 188 321 FCA 29.79 Tx free, 2-yer prourement 11 HIC 1 Government geny 459 DDP 40.93 DDP servie points 12 HIC 1 Government geny 1 700 N/D 44.49 Entry tx free Medin 17.20 WAP 13.16 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.7. DTP-IPV No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 UMIC 1 Government geny 1 500 000 DDP 8.72 2 HIC 1 Government geny 68 092 DDP 9.23 3 HIC 1 Government geny 116 252 DDP 12.64 4 HIC 1 Government geny 15 000 FCA 12.67 5 HIC 1 Government geny 186 000 DDP 14.68 6 HIC 1 Government geny 5 612 N/D 16.14 7 HIC N/D Government geny 400 EXW 22.97 8 HIC 1 Government geny 50 326 DAP 23.24 Phrmy prie 9 HIC 1 Government geny 22 022 DDP 30.23 DDP servie points Medin 14.68 WAP 10.20 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue TABLE A3.8. DT-IPV No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 HIC 1 Government geny 200 000 DDP 8.10 Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue

APPENDIX 3 29 TABLE A3.9. DTwP No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LMIC 10 UNICEF SD 48 000 CIF 0.10 Inludes 10% VAT & 3% exise tx 2 LIC 10 UNICEF SD 186 000 FCA 0.20 3 LMIC 10 UNICEF SD 550 000 FCA 0.20 4 LIC 10 UNICEF SD 240 000 FCA 0.23 5 LMIC 10 Government geny 49 500 DDP 0.53 6 UMIC 10 Government geny 150 000 DDP 0.68 7 LMIC 1 Government geny 30 000 DDP 1.26 8 HIC 1 Government geny 450 000 N/A 3.08 Medin 0.38 WAP 1.03 N/A: not pplile. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.10. DTwP-Hi-HepB No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LMIC 10 UNICEF SD 1 600 000 N/D 2.14 GAVI prie 2 LIC 1 UNICEF SD 44 100 FCA 2.40 GAVI prie 3 LIC 1 UNICEF SD 633 100 FCA 2.61 GAVI prie 4 LMIC 1 UNICEF SD 58 450 CIF 2.70 Inludes 10% VAT & 3% exise tx 5 LIC 1 UNICEF SD 100 000 FCA 2.70 GAVI prie 6 LIC 1 UNICEF SD 160 600 FCA 2.70 GAVI prie 7 LIC 1 UNICEF SD 100 000 FCA 2.70 GAVI prie 8 LIC 1 UNICEF SD 42 100 FCA 2.70 GAVI prie 9 LMIC 1 UNICEF SD 49 950 CIP 2.79 GAVI prie 10 LMIC 1 UNICEF SD 89 050 CIP 2.79 GAVI prie 11 LMIC 2 UNICEF SD 97 300 CIF 2.95 GAVI prie Medin 2.70 WAP 2.39 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue.

30 REVIEW OF VACCINE PRICE DATA TABLE A3.11. HepA No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 UMIC 1 Government geny 3 000 000 DDP 7.45 2 HIC N/D Government geny 129 504 FCA 18.39 Tx free, 2-yer prourement 3 HIC 1 Government geny 104 DDP 22.58 4 HIC 1 N/D 91 DAP 23.85 5 HIC N/D Government geny 50 EXW 25.40 6 HIC 1 Government geny 388 DDP 34.26 Medin 23.21 WAP 7.91 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.12. HepAHepB No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 HIC 1 Government geny 288 DDP 26.96 Peditri 2 HIC 1 Government geny 2 800 DDP 36.57 Adult 3 HIC 1 N/D 370 DAP 45.16 Medin 36.57 WAP 36.69 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.13. HepB_dult No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LMIC 1 Government geny 155 700 DDP 1.11 2 HIC 1 Government geny 20 301 DDP 9.08 3 HIC 1 N/D 4 433 DAP 9.08 4 HIC N/D Government geny 289 696 FCA 10.15 Tx free, 2-yer prourement 5 HIC 1 Government geny 6 300 DDP 13.28 6 HIC 1 Government geny 150 N/D 13.74 Entry tx free 7 HIC N/D Government geny 50 EXW 17.56 8 HIC 1 Government geny 428 DDP 19.58 DDP servie points Medin 11.71 WAP 7.19 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue.

APPENDIX 3 31 TABLE A3.14. HepB_peditri No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LMIC 10 UNICEF SD 400 000 FCA 0.16 2 LIC 1 UNICEF SD 240 000 FCA 0.37 3 LMIC 1 UNICEF SD 19 500 CIF 0.38 Inludes 10% VAT 4 LMIC 1 UNICEF SD 50 000 CIF 0.38 5 LIC 1 UNICEF SD 170 000 FCA 0.38 6 UMIC 2 Government geny 639 800 DDP 0.49 7 LMIC 1 Government geny 30 000 DDP 0.80 8 UMIC 1 Government geny 7 000 000 DDP 1.00 9 UMIC 1 Government geny 114 300 N/D 1.80 10 HIC 1 Government geny 709 307 N/A 2.19 & 3% exise tx 11 HIC 1 Government geny 2 468 DDP 3.41 DDP servie points 12 HIC 1 Government geny 67 000 FCA 3.56 13 UMIC 1 Government geny 65 000 DDP 4.50 14 HIC 1 Government geny 281 188 DDP 5.90 15 HIC 1 N/D 55 130 DAP 6.17 16 HIC N/D Government geny 524 413 FCA 6.51 Tx free, 17 HIC 1 Government geny N/D DDP 6.71 2-yer prourement 18 HIC 1 Government geny 1 150 N/D 7.04 Entry tx free 19 HIC 1 Government geny 1 300 N/D 7.70 Entry tx free 20 HIC 1 Government geny 7 500 DDP 10.74 21 HIC N/D Government geny 20 EXW 11.95 Medin 3.41 WAP 1.48 N/A: not pplile; N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.15. Hi No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 UMIC 1 Government geny 95 000 DDP 4.03 2 HIC 1 Government geny 568 580 CIF 6.89 3 HIC 1 N/D 395 DAP 8.63 4 HIC N/D Government geny 11 610 FCA 10.21 Tx free, 2-yer prourement 5 HIC N/D Government geny 10 EXW 14.61 6 HIC 1 Government geny 150 DDP 19.26 Medin 9.42 WAP 6.55 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue.

32 REVIEW OF VACCINE PRICE DATA TABLE A3.16. HPV No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 HIC 1 Government geny 116 420 DDP 20.94 2 HIC 1 Government geny 170 000 DDP 22.77 3 HIC 1 Government geny 5 915 N/D 38.07 4 HIC 1 Government geny 16 212 DDP 38.65 DDP servie points 5 HIC 1 Government geny 219 424 DDP 39.71 6 HIC N/D Government geny 352 179 FCA 41.38 Tx free, 7 HIC 1 N/D 17 516 DAP 47.97 8 UMIC 1 Government geny 20 250 DDP 53.97 9 UMIC 1 Government geny 22 050 DDP 53.98 10 HIC N/D Government geny 50 EXW 66.40 11 UMIC 1 Government geny 19 000 DDP 93.40 Medin 41.38 WAP 36.86 1-yer prourement N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.17. Influenz_dult No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 UMIC 1 Government geny 200 000 DDP 2.73 2 HIC 1 N/D 83 400 CIP 3.59 3 HIC 1 Government geny 560 777 DDP 3.76 4 HIC 1 Government geny 594 180 DDP 4.04 5 UMIC 1 Government geny 999 428 DDP 4.48 6 HIC N/D Government geny 2 500 EXW 4.77 7 LMIC PFS Government geny 160 000 DDP 4.95 8 HIC 1 Government geny 1 072 315 DDP 5.13 9 HIC 1 Other 58 649 N/D 5.14 10 LMIC 1 Other 56 922 N/D 14.29 Medin 4.62 WAP 4.55 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.18. Influenz_peditri No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 HIC 1 N/D 350 CIP 5.46 N/A: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue.

APPENDIX 3 33 TABLE A3.19. IPV No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 HIC 1 Government geny N/D DDP 4.94 2 HIC 1 Government geny 640 000 CIF 6.06 3 UMIC 1 Government geny 436 000 N/D 6.48 4 HIC 1 Government geny 1 500 FCA 6.92 5 HIC 1 N/D 255 DAP 7.21 6 HIC N/D Government geny 20 EXW 8.47 7 HIC 1 Government geny 2 025 DDP 10.49 8 HIC 1 Government geny 20 800 DDP 10.56 9 HIC 1 Government geny 24 DDP 12.94 DDP servie points Medin 7.21 WAP 6.32 N/D: no dt or informtion ville. TABLE A3.20. Mesles No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 UMIC 1 Government geny 200 000 DDP 1.44 2 UMIC 2 Government geny 250 000 DDP 2.09 3 HIC 1 N/D 300 CIP 5.98 Medin 2.09 WAP 1.80 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue.

34 REVIEW OF VACCINE PRICE DATA TABLE A3.21. MMR No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LIC 10 UNICEF SD 180 000 FCA 0.98 2 LMIC 10 UNICEF SD 1 358 400 FCA 0.98 3 LMIC 10 Government geny 93 000 DDP 1.97 4 LMIC 1 Government geny 47 000 DDP 3.23 5 LMIC 2 UNICEF SD 37 000 CIF 3.25 Inludes 10% VAT & 3% exise tx 6 LMIC 2 UNICEF SD 20 000 CIF 3.25 7 LMIC 2 UNICEF SD 65 000 CIF 3.25 8 LMIC 2 UNICEF SD 35 000 CIF 3.25 9 UMIC 1 Government geny 679 500 DDP 3.66 10 UMIC 1 Government geny 2 300 000 DDP 4.41 11 HIC 1 N/D 29 710 DAP 5.84 12 HIC 1 Government geny N/D DDP 6.12 13 HIC 1 Government geny 29 000 FCA 6.51 14 HIC 1 Government geny 112 430 DDP 6.61 15 HIC 1 Government geny 965 000 CIF 6.72 16 UMIC 1 Government geny 40 000 DDP 6.87 17 UMIC 1 Government geny 250 000 N/D 7.56 18 HIC 1 Government geny 38 982 DDP 7.63 DDP servie points 19 HIC N/D Government geny 1 352 383 FCA 7.76 Tx free, 2-yer prourement 20 HIC 1 Government geny 264 986 DDP 8.54 21 HIC 1 Government geny 2 100 N/D 9.16 Entry tx free 22 HIC 1 Government geny 380 000 DDP 9.18 23 HIC 1 Government geny 333 DAP 10.16 Phrmy prie 24 HIC 1 Government geny 102 886 DAP 10.16 Phrmy prie 25 HIC 1 Government geny 9 866 N/D 12.28 26 HIC N/D Government geny 600 EXW 14.38 Medin 6.56 WAP 5.06 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.22. MR No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LIC 10 UNICEF SD 160 000 FCA 0.52 LIC 2 LIC 10 Government geny 503 800 FCA 0.60 LIC Medin 0.56 WAP 0.58 Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue.

APPENDIX 3 35 TABLE A3.23. Men AC No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LMIC 10 Other 950 FCA 17.62 Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.24. Men ACWY No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 HIC N/D Government geny 10 EXW 12.19 2 HIC 1 N/D 200 DAP 14.21 3 HIC N/D Government geny 4 500 FCA 42.76 Tx free, 2-yer prourement Medin 14.21 WAP 41.48 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.25. MenC_onj No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 HIC 1 Government geny 126 148 DDP 10.76 2 HIC 1 Government geny 180 000 DDP 19.12 3 HIC N/D Government geny 2 105 500 FCA 19.19 Tx free, 2-yer prourement 4 HIC 1 Government geny 9 463 N/D 20.24 5 HIC 1 Government geny 2 600 N/D 28.88 Entry tx free Medin 19.19 WAP 18.76 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue.

36 REVIEW OF VACCINE PRICE DATA TABLE A3.26. OPV No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LMIC 20 UNICEF SD 2 700 000 FCA 0.14 2 LMIC 10 UNICEF SD 137 000 CIF 0.17 Inludes 10% VAT & 3% exise tx 3 LMIC 10 UNICEF SD 120 000 CIF 0.18 Inludes 10% VAT & 3% exise tx 4 LMIC 10 UNICEF SD 250 000 CIF 0.18 5 LIC 10 UNICEF SD 600 000 FCA 0.18 6 LIC 10 UNICEF SD 1 100 000 FCA 0.21 7 UMIC 10 Government geny 3 600 000 DDP 0.23 8 UMIC 20 Government geny 1 500 000 DDP 0.23 9 UMIC 10,20 Government geny 578 000 DDP 0.28 10 LMIC 10 Government geny 300 000 DDP 0.30 11 UMIC 10 Government geny 180 000 DAP 0.34 12 HIC 10 Government geny 79 000 CIF 7.67 Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. Medin 0.22 WAP 0.26 TABLE A3.27. Pneumo_ps No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 HIC N/D Government geny 373 600 FCA 10.38 Tx free, 2-yer prourement 2 HIC 1 N/D 1 000 CIP 13.68 3 HIC N/D Government geny 80 EXW 22.39 Medin 13.68 WAP 10.40 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue.

APPENDIX 3 37 TABLE A3.28. PCV No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LMIC 1 UNICEF SD 54 000 CIP 3.53 GAVI prie 2 LMIC 1 UNICEF SD 12 600 CIP 3.99 GAVI prie 3 LMIC 1 UNICEF SD 103 500 CIF 16.00 Inludes 10% VAT 4 HIC 1 Government geny 197 080 DDP 30.00 5 HIC 1 Government geny 720 000 DDP 30.25 6 UMIC 1 Government geny 735 200 CIP 41.28 & 3% exise tx 7 HIC 1 Government geny 118 110 DAP 42.49 Phrmy prie 8 HIC 1 N/D 220 DAP 43.96 9 HIC 1 Government geny 52 450 DDP 44.24 DDP servie points 10 HIC 1 Government geny 124 488 CIF 46.77 11 HIC 1 Government geny 12 887 N/D 52.03 12 HIC 1 Government geny 43 023 DAP 56.90 Phrmy prie 13 HIC 1 N/D 1 090 DAP 57.78 14 HIC N/D Government geny 90 EXW 59.49 15 HIC 1 Government geny 2 600 N/D 66.28 Entry tx free Medin 43.96 WAP 35.12 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.29. Rotvirus No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LMIC 1 UNICEF SD 54 000 CIP 2.46 GAVI prie, 2 dose shedule 2 LMIC 1 UNICEF SD 30 000 CIF 2.50 GAVI prie, 2 dose shedule 3 LMIC 1 UNICEF SD 40 500 CIF 2.50 GAVI prie, 2 dose shedule 4 LMIC 1 UNICEF SD 36 000 CIP 2.96 GAVI prie, 2 dose shedule 5 HIC 1 Government geny 60 003 FCA 13.67 3 dose shedule 6 HIC 1 Government geny 160 167 DDP 15.57 3 dose shedule Medin 2.73 WAP 9.80 Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue.

38 REVIEW OF VACCINE PRICE DATA TABLE A3.30. Td No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LMIC 10 UNICEF SD 32 500 CIF 0.10 Inludes 10% VAT & 3% exise tx 2 LMIC 10 UNICEF SD 900 000 FCA 0.11 3 LMIC 10 UNICEF SD 60 000 CIF 0.11 Inludes 10% VAT & 3% exise tx 4 LMIC 10 UNICEF SD 140 000 CIF 0.11 5 LIC 10 UNICEF SD 610 000 FCA 0.11 6 UMIC 2 Government geny 579 200 DDP 0.22 7 LMIC 10 Government geny 380 000 DDP 0.22 8 UMIC 10 Government geny 45 000 DDP 0.42 9 HIC N/D Government geny N/D DDP 0.95 10 HIC 1 Government geny 713 500 N/A 1.07 11 UMIC 1 Government geny 7 000 000 DDP 2.07 12 HIC 1 Government geny 1 386 370 DDP 3.72 13 HIC 1 N/D 57 690 CIP 3.96 14 UMIC 10 Government geny 334 000 N/D 4.35 15 HIC 1 Government geny 188 245 DDP 5.78 16 HIC N/D Government geny 14 802 208 FCA 5.86 Tx free, 2-yer prourement 17 HIC 1 Government geny 20 000 FCA 7.24 18 HIC 1 Government geny 134 292 DDP 8.90 DDP servie points 19 LIC 1 Donor geny 198 240 FCA 21.59 20 LIC 1 Donor geny 218 110 FCA 22.29 Medin 1.57 WAP 4.34 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.31. TdP No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 HIC N/D Government geny 786,512 FCA 10.42 Tx free, 2-yer prourement 2 HIC 1 Government geny 137,960 DDP 10.54 3 HIC 1 N/D 18,000 DAP 10.62 4 HIC 1 Government geny 6,496 N/D 11.62 5 HIC 1 Government geny 25,000 FCA 13.72 6 HIC 1 Government geny 800 N/D 13.94 Entry tx free 7 HIC N/D Government geny 10 EXW 16.53 8 HIC 1 Government geny 52,847 DAP 24.04 Phrmy prie Medin 12.67 WAP 11.23 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue.

APPENDIX 3 39 TABLE A3.32. TT No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 LMIC 10 UNICEF SD 75 000 CIF 0.08 Inludes 10% VAT & 3% exise tx 2 UMIC 10 Government geny 10 000 DAP 0.39 3 HIC 10 Government geny N/D DDP 0.46 4 HIC 1 Government geny 676 000 N/A 0.61 5 LMIC 2 Other 226 594 N/D 1.04 6 HIC N/D Government geny 2 100 EXW 3.98 7 HIC 1 N/D 49 946 CIP 4.02 Medin 0.61 WAP 0.83 N/A: not pplile; N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.33. Typhoid fever No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 UMIC 5 Government geny 22 300 DDP 4.22 2 HIC N/D Government geny 50 EXW 13.88 Medin 9.05 WAP 4.24 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. TABLE A3.34. Vriell No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 UMIC 1 Government geny 4 000 000 DDP 17.35 2 HIC 1 Government geny 15 118 DDP 33.71 DDP servie points 3 HIC 1 N/D 30 DAP 41.17 4 HIC 1 Government geny 82 170 CIF 42.27 5 HIC N/D Government geny 261 301 FCA 50.46 Tx free, 2-yer prourement Medin 41.17 WAP 19.87 N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue.

40 REVIEW OF VACCINE PRICE DATA TABLE A3.35. YF No. Country Vil size Ageny Totl no. Contrted Contrted group vil) the vine doses delivery (US$) 1 HIC N/D Government geny 20 782 FCA 16.23 Tx free, 2-yer prourement N/D: no dt or informtion ville. Bsed on 2012 GNI per pit dt from the World Bnk (2). Bsed on Inoterms 2010 (4). Estimted using World Bnk ntionl urreny exhnge rtes for 2013 (1) nd sorted y vlue. Referenes 1. Offiil exhnge rte (LCU per US$, period verge) [online dtset]. The World Bnk. Wshington (DC): World Bnk; 2015 (http://pi.worldnk.org/ountries/inditors/ DPANUSLCU?per_pge=30000∓dte=2005:2013, essed 3 Mrh 2015). 2. Gross ntionl inome per pit 2012, Atls method nd PPP. Wshington (DC): World Development Inditors dtse, World Bnk, 17 Deemer 2013; (http://dt.worldnk. org/inditor/ny.gnp.pcap.cd/ountries?disply=defult, essed 10 April 2015). 3. GNI per pit, Atls method (urrent US$), World Development Inditors dtse, World Bnk, 17 Deemer 2013; (http://dt.worldnk.org/inditor/ny.gnp.pcap.cd/ ountries?disply=defult, essed 10 April 2015) 4. Vine prie dt. In: UNICEF [wesite]. Copenhgen: United Ntions Children s Fund; 2015 (http://www.unief.org/supply/index_57476.html, essed 3 Mrh 2015). 5. Inoterms 2010 English Edition. Pris: ICC Servies/Pulitions; 2010 (http://store.iwo.org/inoterms-2010, essed 3 Mrh 2015).

APPENDIX 4 41 Appendix 4. Ntionl urreny exhnge rtes to US dollrs TABLE A4.1. Curreny exhnge rtes Country Ntionl urreny unit (US$) Alni 105.6868952 Andorr 0.753044299 Armeni 409.6257493 Austri 0.753044299 Azerijn 0.783989877 Belrus 31.86116229 Belgium 0.753044299 Bosni nd Herzegovin 1.472875868 Bulgri 1.472850962 Croti 5.706861977 Cyprus 0.753044299 Czeh Repuli 19.5569568 Denmrk 5.616163495 Estoni 0.753044299 Finlnd 0.753044299 Frne 0.753044299 Georgi 1.663217208 Germny 0.753044299 Greee 0.753044299 Hungry 223.5797258 Ielnd 122.1498011 Irelnd 0.753044299 Isrel 3.609613389 Itly 0.753044299 Kzkhstn 152.2029076 Kyrgyzstn 48.4355765 Ltvi 0.514933059 Lithuni 2.60012939 Luxemourg 0.753044299 Mlt 0.753044299 Mono Montenegro Netherlnds 0.753044299 Norwy 5.877132471 Polnd 3.159547548 Portugl 0.753044299 Repuli of Moldov 12.5176209 Romni 3.327299041

42 REVIEW OF VACCINE PRICE DATA TABLE A4.1. ontd Country Ntionl urreny unit (US$) Russin Federtion 31.86116229 Sn Mrino 0.753044299 Seri 85.16711863 Slovki 0.753044299 Sloveni 0.753044299 Spin 0.753044299 Sweden 6.512863035 Switzerlnd 0.926714741 Tjikistn 4.764233333 The former Yugoslv Repuli of Medoni 46.52953394 Turkey 1.905672178 Turkmenistn Ukrine 8.154950542 United Kingdom 0.639561394 Uzekistn 2092.344834 Soure: Offiil exhnge rte (LCU per US$, period verge) [online dtset]. Wshington (DC): World Bnk; 2015 (http://pi.worldnk.org/ountries/inditors/dpanuslcu?per_pge=30000∓dte=2005:2013).

APPENDIX 5 43 Appendix 5. Clssifition of Memer Sttes y ountry inome group TABLE A5.1. Clssifition of ountries Country GNI per pit (US$) Inome group Alni 4030 LMIC Andorr N/D HIC Armeni 3720 LMIC Austri 47660 HIC Azerijn 6220 UMIC Belrus 6530 UMIC Belgium 44660 HIC Bosni nd Herzegovin 4750 UMIC Bulgri 6840 UMIC Croti 13490 HIC Cyprus 26110 HIC Czeh Repuli 18120 HIC Denmrk 59850 HIC Estoni 16150 HIC Finlnd 46490 HIC Frne 41750 HIC Georgi 3270 LMIC Germny 44260 HIC Greee 23260 HIC Hungry 12380 UMIC Ielnd 38330 HIC Irelnd 39110 HIC Isrel 28380 HIC Itly 33860 HIC Kzkhstn 9780 UMIC Kyrgyzstn 990 LIC Ltvi 14120 HIC Lithuni 13830 HIC Luxemourg 71620 HIC Mlt 19760 HIC Mono N/D HIC Montenegro 7220 UMIC Netherlnds 47970 HIC Norwy 98860 HIC Polnd 12660 HIC Portugl 20620 HIC Repuli of Moldov 2070 LMIC Romni 8820 UMIC

44 REVIEW OF VACCINE PRICE DATA TABLE A5.1. ontd Country GNI per pit (US$) Inome group Russin Federtion 12700 HIC Sn Mrino N/D HIC Seri 5280 UMIC Slovk Repuli 17180 HIC Sloveni 22800 HIC Spin 29620 HIC Sweden 55970 HIC Switzerlnd 80970 HIC Tjikistn 860 LIC The former Yugoslv Repuli of Medoni 4620 UMIC Turkey 10830 UMIC Turkmenistn 5410 UMIC Ukrine 3500 LMIC United Kingdom 38670 HIC Uzekistn 1720 LMIC LIC: low-inome ountry (GNI = US$ 1035 or less) LMIC: lower-middle-inome ountry (GNI = US$ 1036 4085) UMIC: upper-middle-inome ountry (GNI = US$ 4086 12 615) HIC: high-inome ountry (GNI = US$ 12 616 or more) N/D - No GNI per pit dt ville. Estimted to e high inome. Soure: GNI per pit, Atls method (urrent US$), World Development Inditors dtse, World Bnk, 17 Deemer 2013; (http://dt.worldnk.org/inditor/ny.gnp.pcap.cd/ountries?disply=defult, essed 10 April 2015).

APPENDIX 6 45 Appendix 6. List of WHO prequlified vines s of 1 Jnury 2015 1 TABLE A6.1. WHO prequlified vines Doses/ primry Vine Mnufturer nme Presenttion ontiner BCG Jpn BCG Lortory Ampoule 20 Ntionl Center of Infetious nd Prsiti Diseses Ampoule 10 Ntionl Center of Infetious nd Prsiti Diseses Ampoule 20 Serum Institute of Indi Limited Vil 20 Sttens Serum Institut Two vil set (tive + exipient) 10 Choler: intivted orl Cruell Sweden AB Vil + Buffer Shet 1 Shnth Biotehnis Limited Vil 1 Diphtheri tetnus Bio Frm Vil 10 Ntionl Center of Infetious nd Prsiti Diseses Vil 10 Ntionl Center of Infetious nd Prsiti Diseses Vil 20 Snofi Psteur SA Vil 10 Snofi Psteur SA Vil 20 Serum Institute of Indi Limited Ampoule 1 Serum Institute of Indi Limited Vil 10 Serum Institute of Indi Limited Vil 20 Diphtheri tetnus (for dults) Bio Frm Vil 10 Biologil E. Limited Vil 1 Biologil E. Limited Vil 10 Ntionl Center of Infetious nd Prsiti Diseses Vil 10 Ntionl Center of Infetious nd Prsiti Diseses Vil 20 Snofi Psteur SA Vil 10 Serum Institute of Indi Limited Ampoule 1 Serum Institute of Indi Limited Vil 10 Serum Institute of Indi Limited Vil 20 Diphtheri tetnus pertussis (whole ell) Bio Frm Vil 10 Biologil E. Limited Vil 1 Biologil E. Limited Vil 10 Snofi Psteur SA Ampoule 1 Snofi Psteur SA Vil 10 Snofi Psteur SA Vil 20 Serum Institute of Indi Limited Ampoule 1 Serum Institute of Indi Limited Vil 10 Serum Institute of Indi Limited Vil 20 1 WHO prequlified vines [online dtset]. Genev: World Helth Orgniztion; 2015 (http://www.who.int/immuniztion_stndrds/vine_qulity/pq_vine_list_en/en/, essed 25 Ferury 2015).

46 REVIEW OF VACCINE PRICE DATA TABLE A6.1. ontd Doses/ primry Vine Mnufturer nme Presenttion ontiner Diphtheri tetnus pertussis (whole Novrtis Vines & Dignostis Srl Vil 1 ell) Hemophilus influenze type Novrtis Vines & Dignostis Srl Vil 10 Snofi Psteur SA Two vil set (tive + tive) 10 Snofi Psteur SA Vil + Ampoule 1 Serum Institute of Indi Limited Two vil set (tive + tive) 1 Diphtheri tetnus pertussis Bio Frm Vil 5 (whole ell) heptitis B Bio Frm Vil 10 GlxoSmithKline Biologils SA Vil 1 GlxoSmithKline Biologils SA Vil 2 GlxoSmithKline Biologils SA Vil 10 Serum Institute of Indi Limited Ampoule 1 Serum Institute of Indi Limited Vil 10 Serum Institute of Indi Limited Vil 20 Diphtheri tetnus pertussis (whole ell) Bern Bioteh Kore Corp. Vil 1 heptitis B Hemophilus influenze type Bern Bioteh Kore Corp. Compt Prefilled Auto-disle Devie 1 Bio Frm Vil 5 Bio Frm Vil 10 Biologil E. Limited Two vil set (tive + tive) 1 Biologil E. Limited Two vil set (tive + tive) 10 Biologil E. Limited Vil 1 Biologil E. Limited Vil 10 GlxoSmithKline Biologils SA Two vil set (tive + tive) 1 GlxoSmithKline Biologils SA Two vil set (tive + tive) 2 LG Life Sienes Vil 1 LG Life Sienes Vil 2 Pne Biote Vil 1 Pne Biote Vil 10 Serum Institute of Indi Limited Two vil set (tive + tive) 1 Serum Institute of Indi Limited Two vil set (tive + tive) 2 Serum Institute of Indi Limited Two vil set (tive + tive) 10 Serum Institute of Indi Limited Vil 1 Serum Institute of Indi Limited Vil 2 Serum Institute of Indi Limited Vil 10 Shnth Biotehnis Privte Ltd. Vil 1 Shnth Biotehnis Privte Ltd. Vil 10 Diphtheri tetnus pertussis (ellulr) GlxoSmithKline Biologils SA Vil 1 Hemophilus influenze type Centro de Ingenirí Genéti y Biotenologí Vil 1 GlxoSmithKline Biologils SA Vil 1 GlxoSmithKline Biologils SA Vil 2 GlxoSmithKline Biologils SA Vil 10 Merk & Co., In. Vil 1 Novrtis Vines & Dignostis Srl Vil 1 Snofi Psteur SA Vil 1 Snofi Psteur SA Vil 10 Serum Institute of Indi Limited Vil 1 Heptitis A (dult) GlxoSmithKline Biologils SA Vil 1 Heptitis A (junior) GlxoSmithKline Biologils SA Vil 1 Heptitis B Bern Bioteh Kore Corp. Vil 1 Bern Bioteh Kore Corp. Vil (thiomersl free) 1 Bern Bioteh Kore Corp. Vil 2 Bern Bioteh Kore Corp. Vil 10 Bio Frm Unijet 1

APPENDIX 6 47 TABLE A6.1. ontd Doses/ primry Vine Mnufturer nme Presenttion ontiner Heptitis B Centro de Ingenirí Genéti y Biotenologí Vil 1 Centro de Ingenirí Genéti y Biotenologí Vil 10 GlxoSmithKline Biologils SA Vil 1 GlxoSmithKline Biologils SA Vil 10 GlxoSmithKline Biologils SA Vil 20 LG Life Sienes Vil 1 LG Life Sienes Vil 2 LG Life Sienes Vil 6 LG Life Sienes Vil 10 Serum Institute of Indi Limited Vil 10 Serum Institute of Indi Limited Ampoule or Vil 1 Serum Institute of Indi Limited Vil 10 Serum Institute of Indi Limited Ampoule or Vil 1 Shnth Biotehnis Limited Vil 1 Shnth Biotehnis Limited Vil 2 Shnth Biotehnis Limited Vil 6 Shnth Biotehnis Limited Vil 10 Shnth Biotehnis Limited Vil 20 HPV GlxoSmithKline Biologils SA Vil 1 Influenz sesonl GlxoSmithKline Biologils SA Vil 2 Merk & Co., In. Vil 1 GlxoSmithKline Biologils-Cnd Vil 10 Green Cross Corportion Vil 1 Green Cross Corportion Vil 10 Novrtis Vines & Dignostis Ltd Vil 10 Snofi Psteur SA Vil 10 Snofi Psteur-USA Vil 1 Snofi Psteur-USA Vil 10 Influenz, pndemi H1N1 CSL Limited A.C.N. 051 588 348 Vil 10 GlxoSmithKline Biologils-Germny Two vil set (tive + djuvnt) 10 Green Cross Corportion Vil 1 MedImmune Spryer 1 Novrtis Vines & Dignostis Ltd Vil 10 Novrtis Vines nd Dignostis Vil 17 Novrtis Vines nd Dignostis S.r.l. Vil 10 Snofi Psteur SA Vil 10 Snofi Psteur-USA Vil 1 Snofi Psteur-USA Vil 10 Serum Institute of Indi Limited Vil + Ampoule 1 Serum Institute of Indi Limited Vil + Ampoule 5 Jpnese enephlitis Biologil E Limited Vil 1 Chengdu Institute of Biologil Produts Co. Ltd Chin Vil 1 Chengdu Institute of Biologil Produts Co. Ltd Chin Vil 5 GPO-MBP Government Phrmeutil Orgniztion Merieux Biologil Produts Compny Limited Vil 4 Mesles Bio Frm Vil 10

48 REVIEW OF VACCINE PRICE DATA TABLE A6.1. ontd Doses/ primry Vine Mnufturer nme Presenttion ontiner Mesles Bio Frm Vil 20 GPO-MBP Co., Ltd. Vil 10 Snofi Psteur SA Vil 10 Serum Institute of Indi Limited Vil 1 Serum Institute of Indi Limited Vil 2 Serum Institute of Indi Limited Vil 5 Serum Institute of Indi Limited Vil 10 Mesles nd ruell Serum Institute of Indi Limited Vil 1 Serum Institute of Indi Limited Vil 2 Serum Institute of Indi Limited Vil 5 Serum Institute of Indi Limited Vil 10 Mesles, mumps nd ruell GlxoSmithKline Biologils SA Vil 1 GlxoSmithKline Biologils SA Vil 2 Merk & Co., In. Vil 1 Snofi Psteur SA Vil 1 Snofi Psteur SA Vil 10 Serum Institute of Indi Limited Vil 1 Serum Institute of Indi Limited Vil 2 Serum Institute of Indi Limited Vil 5 Serum Institute of Indi Limited Vil 10 Meningool A onjugte Serum Institute of Indi Limited Vil 10 Meningool A+C BioMnguinhos Vil 10 Snofi Psteur SA Vil 10 Meningool ACYW-135 (polyshride) Snofi Psteur-USA Two vil set (tive + exipient) 10 Meningool ACYW-135 (onjugte) Novrtis Vines nd Dignostis Two vil set (tive + tive) 1 Snofi Psteur SA Vil 1 Pneumool (onjugte) GlxoSmithKline Biologils SA Vil (10 vlent) 1 GlxoSmithKline Biologils SA Vil (10 vlent) 2 Pfizer Vil (13 vlent) 1 Pfizer Vil (7 vlent) 1 Polio vine intivted (IPV) Bilthoven Biologils Vil 1 Bilthoven Biologils Vil 5 GlxoSmithKline Biologils SA Vil 1 GlxoSmithKline Biologils SA Vil 2 Snofi Psteur SA Vil 10 Sttens Serum Institut Vil 1 Polio vine orl (OPV) Bio Frm Vil 20 ivlent types 1 nd 3 GlxoSmithKline Biologils SA Vil 10 GlxoSmithKline Biologils SA Vil 20 Hffkine Bio Phrmeutil Corportion Ltd Vil 20 Novrtis Vines nd Dignostis S.r.l. Plsti Tue 20 Snofi Psteur SA Vil 20 Serum Institute of Indi Limited Vil 10 Serum Institute of Indi Limited Vil 20 Polio vine orl (OPV) monovlent type 1 Bio Frm Vil 20 GlxoSmithKline Biologils SA Vil 10 GlxoSmithKline Biologils SA Vil 20 Hffkine Bio Phrmeutil Corportion Ltd Vil 20 Novrtis Vines & Dignostis Srl Plsti Tue 20 Snofi Psteur SA Vil 20

APPENDIX 6 49 TABLE A6.1. ontd Doses/ primry Vine Mnufturer nme Presenttion ontiner Polio vine orl (OPV) monovlent type 2 GlxoSmithKline Biologils SA Vil 20 GlxoSmithKline Biologils SA Vil 10 Polio vine orl (OPV) monovlent type 3 GlxoSmithKline Biologils SA Vil 10 GlxoSmithKline Biologils SA Vil 20 Polio vine orl (OPV) trivlent Bio Frm Vil 10 Bio Frm Vil 20 GlxoSmithKline Biologils SA Vil 10 GlxoSmithKline Biologils SA Vil 20 Hffkine Bio Phrmeutil Corportion Ltd Vil 20 Novrtis Vines & Dignostis Srl Plsti Tue 10 Novrtis Vines & Dignostis Srl Plsti Tue 20 Snofi Psteur SA Vil 10 Snofi Psteur SA Vil 20 Serum Institute of Indi Limited Vil 10 Serum Institute of Indi Limited Vil 20 Ries Zydus Cdil Vil 1 Chiron Behring Vines Privte Ltd. Vil 1 Novrtis Vines nd Dignostis Vil 1 Snofi Psteur SA Vil 1 Rotvirus GlxoSmithKline Biologils SA Plsti Tue 1 GlxoSmithKline Biologils SA Applitor 1 GlxoSmithKline Biologils SA Vil 1 Merk & Co., In. Plsti Tue 1 Ruell Serum Institute of Indi Limited Vil 1 Serum Institute of Indi Limited Vil 2 Serum Institute of Indi Limited Vil 5 Serum Institute of Indi Limited Vil 10 Tetnus toxoid Bio Frm Vil 10 Bio Frm Vil 20 Bio Frm Unijet 1 Biologil E. Limited Vil 20 Biologil E. Limited Vil 1 Biologil E. Limited Vil 10 Ntionl Center of Infetious nd Prsiti Diseses Vil 10 Ntionl Center of Infetious nd Prsiti Diseses Vil 20 Snofi Psteur SA Vil 10 Snofi Psteur SA Vil 20 Serum Institute of Indi Limited Ampoule 1 Serum Institute of Indi Limited Vil 10 Serum Institute of Indi Limited Vil 20 Shnth Biotehnis Limited Vil 10 Shnth Biotehnis Limited Vil 20 Typhoid Snofi Psteur SA Vil 20 Yellow fever BioMnguinhos Vil 5 BioMnguinhos Vil 10 BioMnguinhos Vil 50 Federl Stte Unitry Enterprise of Chumkov Institute of Poliomyelitis nd Vir Enephlitides of Russin Ad. Med. Si. Ampoule 2

50 REVIEW OF VACCINE PRICE DATA TABLE A6.1. ontd Doses/ primry Vine Mnufturer nme Presenttion ontiner Yellow fever Federl Stte Unitry Enterprise of Chumkov Institute of Poliomyelitis nd Virl Enephlitides of Russin Ad. Med. Si. Ampoule 5 Federl Stte Unitry Enterprise of Chumkov Institute of Poliomyelitis nd Virl Enephlitides of Russin Ad. Med. Si. Ampoule 10 Institut Psteur de Dkr Vil 5 Institut Psteur de Dkr Vil 20 Institut Psteur de Dkr Vil 10 Snofi Psteur SA Vil 10

APPENDIX 7 51 Appendix 7. Other vine prie dt soures 1. CDC vine prie list. In: Centers for Disese Control nd Prevention [wesite]. Atlnt, GA: Centers for Disese Control nd Prevention; 2015 (http://www.d.gov/vines/progrms/vf/wrdees/vine-mngement/prie-list/). 2. PAHO Revolving Fund. In: Pn Amerin Helth Orgniztion [wesite]. Wshington, DC: Pn Amerin Helth Orgniztion; 2015 (http://www.pho.org/hq/index.php?option=om_ ontent&view=rtile&id=1864&itemid=40713&lng=en). 3. Vine prie dt. In: UNICEF [wesite]. New York, NY: United Ntions Children s Fund; 2015 (http://www.unief.org/supply/index_57476.html). 4. Vine Produt, Prie nd Prourement (V3P) we pltform. In: World Helth Orgniztion [wesite]. Genev: World Helth Orgniztion; 2015 (http://www.who.int/immuniztion/progrmmes_systems/prourement/v3p/pltform/en/).

The WHO Regionl Offie for Europe The World Helth Orgniztion (WHO) is speilized geny of the United Ntions reted in 1948 with the primry responsiility for interntionl helth mtters nd puli helth. The WHO Regionl Offie for Europe is one of six regionl offies throughout the world, eh with its own progrmme gered to the prtiulr helth onditions of the ountries it serves. Memer Sttes Alni Andorr Armeni Austri Azerijn Belrus Belgium Bosni nd Herzegovin Bulgri Croti Cyprus Czeh Repuli Denmrk Estoni Finlnd Frne Georgi Germny Greee Hungry Ielnd Irelnd Isrel Itly Kzkhstn Kyrgyzstn Ltvi Lithuni Luxemourg Mlt Mono Montenegro Netherlnds Norwy Polnd Portugl Repuli of Moldov Romni Russin Federtion Sn Mrino Seri Slovki Sloveni Spin Sweden Switzerlnd Tjikistn The former Yugoslv Repuli of Medoni Turkey Turkmenistn Ukrine United Kingdom Uzekistn World Helth Orgniztion Regionl Offie for Europe UN City, Mrmorvej 51, DK-2100 Copenhgen Ø, Denmrk Tel.: +45 45 33 70 00 Fx: +45 45 33 70 01 Emil: ontt@euro.who.int Wesite: www.euro.who.int ISBN 978-92-890-5107-1 9 789289 051071 >